Etidronate disodium hydrate
SIGMA/P5248 - ≥97% (NMR), solid
Synonym: Dihydrogen (1-
CAS Number: 7414-83-7 (anhydrous)
Empirical Formula (Hill Notation): C2H6Na2O7P2 · xH2O
Molecular Weight: 249.99 (anhydrous basis)
EC Number: 231-025-7
MDL Number: MFCD00152567
Linear Formula: C2H6Na2O7P2 · xH2O
Product Type: Chemical
| assay | ≥97% (NMR) |
| color | white |
| form | solid |
| InChI | 1S/C2H8O7P2.2Na/c1-2(3,10 |
| InChI key | GWBBVOVXJZATQQ-UHFFFAOYSA |
| mp | >300 °C |
| Quality Level | 100  |
| SMILES string | [Na+].[Na+].CC(O)(P(O)([O |
| solubility | H2O: ≥10 mg/mL |
| storage temp. | 2-8°C |
| Application: | Etidronate disodium hydrate has been used in the synthesis of bisphosphonate derivatives of adenosine triphosphate (ATP)by T4 RNA ligase. It has also been sued to inhibit human farnesyl diphosphate synthase (FDPS). |
| Biochem/physiol Actions: | Bisphosphonate antiresorptive agent. Less potent inhibitor of farnesyl diphosphate synthase (IC50 = 80 μM) as compared to the nitrogen containing bisphosphonates |
| Biochem/physiol Actions: | Etidronate helps to guard chronic ocular hypertension prompted retinal oxidative stress. It stimulates the development of retinal ganglion cells through insulin-like growth factor 1 (IGF-1) signaling pathway. It may possess neuroprotective effects in in vivo and in vitro rat model of glaucoma. Etidronate belongs to bisphosphonates. |
| Packaging: | 10, 100 mg in glass bottle |
| Symbol |  GHS07 |
| Signal word | Warning |
| Hazard statements | H302 |
| Hazard Codes | Xn |
| Risk Statements | 22 |
| RIDADR | NONH for all modes of transport |
| WGK Germany | WGK 1 |
| Flash Point(F) | Not applicable |
| Flash Point(C) | Not applicable |
| Purity | ≥97% (NMR) |
| mp | >300 °C |
| Storage Temp. | 2-8°C |
| UNSPSC | 12352200 |